Masimo Corp (NASDAQ: MASI)‘s stock had its “neutral” rating reaffirmed by Zacks in a note issued to investors on Monday, Analyst Ratings.Net reports. They currently have a $23.00 target price on the stock. Zacks‘ price objective would indicate a potential upside of 6.43% from the company’s current price.
A number of other firms have also recently commented on MASI. Analysts at TheStreet upgraded shares of Masimo Corp from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, May 15th. Separately, analysts at Citigroup upgraded shares of Masimo Corp from a “sell” rating to a “neutral” rating in a research note to investors on Friday, May 3rd. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of Masimo Corp in a research note to investors on Tuesday, April 9th. They set a “buy” rating on the stock.
One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Masimo Corp currently has an average rating of “Hold” and an average price target of $23.00.
Shares of Masimo Corp (NASDAQ: MASI) traded up 0.46% during mid-day trading on Monday, hitting $21.71. Masimo Corp has a 52 week low of $18.20 and a 52 week high of $25.35. The stock’s 50-day moving average is currently $19.90. The company has a market cap of $1.229 billion and a P/E ratio of 20.01.
Masimo Corp (NASDAQ: MASI) last released its earnings data on Thursday, May 2nd. The company reported $0.28 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.28. The company had revenue of $135.90 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter last year, the company posted $0.27 earnings per share. Masimo Corp’s revenue was up 14.0% compared to the same quarter last year. Analysts expect that Masimo Corp will post $1.14 EPS for the current fiscal year.
Masimo Corporation is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring products that improve patient care.
To view Zacks’ full report, visit www.zacks.com